KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Other Operating Expenses: 2017-2024

Historic Other Operating Expenses for Adaptive Biotechnologies (ADPT) over the last 8 years, with Dec 2024 value amounting to $165.7 million.

  • Adaptive Biotechnologies' Other Operating Expenses rose 12.29% to $42.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.5 million, marking a year-over-year decrease of 13.92%. This contributed to the annual value of $165.7 million for FY2024, which is 13.34% down from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Other Operating Expenses of $165.7 million as of FY2024, which was down 13.34% from $191.3 million recorded in FY2023.
  • Over the past 5 years, Adaptive Biotechnologies' Other Operating Expenses peaked at $191.3 million during FY2023, and registered a low of $85.6 million during FY2020.
  • For the 3-year period, Adaptive Biotechnologies' Other Operating Expenses averaged around $170.7 million, with its median value being $165.7 million (2024).
  • As far as peak fluctuations go, Adaptive Biotechnologies' Other Operating Expenses surged by 71.12% in 2021, and later declined by 13.34% in 2024.
  • Adaptive Biotechnologies' Other Operating Expenses (Yearly) stood at $85.6 million in 2020, then spiked by 71.12% to $146.5 million in 2021, then climbed by 5.97% to $155.2 million in 2022, then rose by 23.23% to $191.3 million in 2023, then dropped by 13.34% to $165.7 million in 2024.